LMO2 and leukemia: Although the retrovirus-based treatment of children with X-linked severe combined immunodeficiency (SCID-X1) was successful, the insertion of the therapeutic gene into the LMO2 proto-oncogene region of the genome led to the development of leukemia in a few patients [8].